This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
J&J (JNJ) to Commence Pharma Q2 Earnings Season: What's Up?
by Zacks Equity Research
Johnson & Johnson (JNJ), a healthcare bellwether, will report second-quarter 2017 results on Jul 18.
The Zacks Analyst Blog Highlights: Wells Fargo, Broadcom, Gilead, NextEra Energy and Emerson Electric
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Wells Fargo, Broadcom, Gilead, NextEra Energy and Emerson Electric
Top Stock Reports for Wells Fargo, Broadcom & Gilead
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), Broadcom (AVGO) and Gilead (GILD).
Galapagos-Gilead Begin Phase II Study on Uveitis Candidate
by Zacks Equity Research
Galapagos NV (GLPG) has announced initiation of a new phase II study, evaluating its lead pipeline candidate filgotinib for treatment of adult patients with non-infectious uveitis.
Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod
by Arpita Dutt
Key highlights in the biotech sector include FDA approval for Portola's (PTLA) anticoagulant and EU approval for Regeneron's rheumatoid arthritis (RA) drug.
Gilead's (GILD) HCV Drug Application Accepted in the EU
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) announced that the CHMP has adopted a positive opinion on the company's application for HCV drug Vosevi.
AbbVie's HCV Combo Drug Gets Positive CHMP Opinion in EU
by Zacks Equity Research
AbbVie Inc. (ABBV) announced that the CHMP of the EMA has recommended marketing approval of its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P).
Stock Market News for June 23, 2017
by Zacks Equity Research
The Nasdaq finished in the green for consecutive sessions on Thursday, boosted primarily by gain in health care shares
How to Find the Best Value Stocks
by Tracey Ryniec
A great value stock isn't just a cheap stock. Tracey uses a "secret sauce" to find the hidden gems among the cheap stocks.
Biotech Stock Roundup: Clovis Soars on Rubraca Data, Seattle Hit by Study Halt
by Arpita Dutt
Key highlights in the biotech sector include positive data on Clovis' (CLVS) PARP inhibitor, Rubraca.
Gilead's (GILD) HBV Drug Vemlidy Receives Approval in Canada
by Zacks Equity Research
Health Canada granted a Notice of Compliance (NOC) for Vemlidy 25mg tablets, a once-daily treatment for adults with chronic HBV infection with compensated liver disease.
Is Gilead Sciences a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if Gilead Sciences Inc. (GILD) stock is a good choice for value-oriented investors right now from multiple angles.
Epizyme Provides Positive Interim Data on EZH2 Inhibitor
by Zacks Equity Research
Epizyme, Inc. (EPZM) announced positive interim data from an ongoing phase II study evaluating pipeline candidate tazemetostat as a monotherapy in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma
Biotech Stock Roundup: Management Changes at Biogen, Alexion, GILD Files HIV Drug
by Arpita Dutt
Key highlights in the biotech sector include management changes for Biogen (BIIB) and Alexion as well as a regulatory filing for Gilead's HIV regimen.
Gilead (GILD) Submits NDA for HIV Combination Therapy Regimen
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) announced that it has submitted a NDA to the FDA for an investigational HIV combination therapy regimen.
The Zacks Analyst Blog Highlights: Gilead, BP, Dow Chemical, America Movil and MetLife
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead, BP, Dow Chemical, America Movil and MetLife
Top Stock Reports for Gilead, BP & Dow Chemical
by Sheraz Mian
Today's Research Daily features new research reports on 17 major stocks, including Gilead (GILD), BP (BP), and Dow Chemical (DOW).
Why Is Gilead Sciences (GILD) Down 3.5% Since the Last Earnings Report?
by Zacks Equity Research
Gilead Sciences (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Gilead Single Tablet Regiment for HIV Good in Phase III
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) reported positive results on four phase III studies evaluating bictegravir in combination with FTC/TAF as a single tablet regimen for HIV infection.
Merck's HIV Drug Isentress Gets FDA Approval for Higher Dose
by Zacks Equity Research
Merck & Co., Inc. (MRK) recently announced that the FDA has approved Isentress HD, a new 1,200 mg once daily dose of its marketed drug Isentress (raltegravir), in combination with other anti-retroviral therapies.
Intercept's (ICPT) Liver Drug Ocaliva Approved in Canada
by Zacks Equity Research
Intercept Pharmaceuticals, Inc. (ICPT) announced that livver drug Ocaliva has obtained approval in Canada also.
Merck's HIV Drug Gets Positive CHMP Opinion for Higher Dose
by Zacks Equity Research
Merck & Co., Inc. (MRK) recently announced that the 600 mg film-coated formulation of its marketed drug, Isentress (raltegravir) in combination with other anti-retroviral therapies, has received positive opinion from CHMP.
Zacks Value Investor Highlights: Avis Budget Group, General Motors, Gilead Sciences, LGI Homes and Micron
by Zacks Equity Research
Zacks Value Investor Highlights: Avis Budget Group, General Motors, Gilead Sciences, LGI Homes and Micron
Value Stock or Value Trap?
by Tracey Ryniec
Tracey tells you how not to get fooled by value trap stocks on this week's podcast.
The Zacks Analyst Blog Highlights: Gilead, Dow Chemical, MetLife, Tesla and Emerson Electric
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead, Dow Chemical, MetLife, Tesla and Emerson Electric